Get started
Author

Yasutaka Watanabe

Observed name: Yasutaka WATANABE
Observed institutions: The University of Texas MD Anderson Cancer Center, Jichi Medical University, Shanghai Jiao Tong University, Chinese Academy of Medical Sciences & Peking Union Medical College, Saitama Prefecture, McGill University Health Centre, Shanghai Chest Hospital, National Cancer Centre Japan, Tokyo Medical University Hachioji Medical Center, Dana-Farber Cancer Institute, Saitama Cancer Center, National Cancer Center Hospital East, Social Insurance Saitama Chuo Hospital, Jichi Medical University Saitama Medical Center, Saitama Cardiovascular and Respiratory Center, Saitama Medical Center, Saitama Medical University, Saitama Medical University
ORCID: 0000-0002-3679-4864
Observed ORCID: 0000-0002-3679-4864
OpenAlex ID: A5111586811
Mammalian target of rapamycin: a central node of complex signaling cascades.
2011 · Yoh Dobashi, Yasutaka Watanabe, et al. · PubMed · 723
Perioperative Nivolumab in Resectable Lung Cancer
2024 · Tina Cascone, Mark M. Awad, et al. · New England Journal of Medicine · 649
PDF
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
2024 · Luis G. Paz-Ares, Oscar Juan-Vidal, et al. · Journal of Clinical Oncology · 167
PDF
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
2021 · Akito Hata, Isamu Okamoto, et al. · Journal of Clinical Oncology · 69
PDF
Multiple, thin-walled cysts are one of the HRCT features of airspace enlargement with fibrosis
2015 · Yasutaka Watanabe, Yoshinori Kawabata, et al. · European Journal of Radiology · 53
Hypercapnic tumor microenvironment confers chemoresistance to lung cancer cells by reprogramming mitochondrial metabolism in vitro
2019 · Ryota Kikuchi, Yuki Iwai, et al. · Free Radical Biology and Medicine · 44
Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
2018 · Fumiaki Kudo, Yasutaka Watanabe, et al. · Internal Medicine · 40
PDF
A clinicopathological study of surgically resected lung cancer in patients with usual interstitial pneumonia
2017 · Yasutaka Watanabe, Yoshinori Kawabata, et al. · Respiratory Medicine · 30
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
2026 · Mariano Provencio, Mark M. Awad, et al. · Nature Cancer · 29
PDF
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC
2025 · Kentaro Tanaka, Jun Sugisaka, et al. · Nature Communications · 28
Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer ( IMpower010 )
2022 · Hirotsugu Kenmotsu, Shunichi Sugawara, et al. · Cancer Science · 25
PDF
Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution
2017 · Nobuyuki Koyama, Yasutaka Watanabe, et al. · Chemotherapy · 25
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.
2024 · Mariano Provencio, Mark M. Awad, et al. · Journal of Clinical Oncology · 23
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)
2022 · Akito Hata, Yoshimasa Shiraishi, et al. · Oncology and Therapy · 19
PDF
Pulmonary Mucosa-associated Lymphoid Tissue (MALT) Lymphoma in Sjögren's Syndrome Showing Only the LIP Pattern Radiologically
2012 · Yasutaka Watanabe, Shinichiro Koyama, et al. · Internal Medicine · 19
PDF
Tracheobronchitis in a Patient with Crohn's Disease
2009 · Takashi Asami, Shinichiro Koyama, et al. · Internal Medicine · 18
PDF
Reactivation of TB During Administration of Durvalumab After Chemoradiotherapy for Non-Small-Cell Lung Cancer: A Case Report
2020 · Yasuhiro Kato, Yasutaka Watanabe, et al. · Immunotherapy · 15
A Phase II Study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutation-Positive NSCLC in Whom Systemic Disease (T790M-Negative) Progressed after Treatment with First- Or Second-Generation EGFR TKIS and Platinum-Based Chemotherapy
2022 · Masayuki Takeda, Mototsugu Shimokawa, et al. · Lung Cancer · 11
PDF
Thymic clear cell carcinoma
2010 · Tomoyuki Nakano, Shunsuke Endo, et al. · General Thoracic and Cardiovascular Surgery · 11
Combined blockade of GPX4 and activated EGFR / HER3 bypass pathways inhibits the development of ALK ‐inhibitor‐induced tolerant persister cells in ALK ‐fusion‐positive lung cancer
2024 · Koh Furugaki, Takaaki Fujimura, et al. · Molecular Oncology · 10
PDF
SIADH is only an Atypical Clinical Feature in a Patient with Prolactinoma
2007 · Tomoyuki Saito, Yasutaka Watanabe, et al. · Internal Medicine · 10
PDF
Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
2016 · Kazuo Umemura, Takayuki Iwaki, et al. · Clinical Pharmacology in Drug Development · 8
PDF
Suppression of Myotonia in Cerebral Palsy and Adjunctive Effect of Low Level Laser Therapy on Intensive Functional Training
2005 · Yoshimi Asagai, Yasutaka Watanabe, et al. · LASER THERAPY · 8
PDF
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al. · Clinical Cancer Research · 7
A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.
2023 · Shintaro Kanda, Seiji Niho, et al. · Journal of Clinical Oncology · 7
Works count: 75
Citation count: 2,120
H-index: 16
I10-index: 21
Year
Topic
Type